VLA15 + Placebo

Phase 3Recruiting

0 views this week 0 watching⚡ Active

Interest: 47/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Lyme Borreliosis

Conditions

Lyme Borreliosis

Trial Timeline

Nov 19, 2025 → Feb 14, 2028

NCT ID

NCT07226882

About VLA15 + Placebo

VLA15 + Placebo is a phase 3 stage product being developed by Pfizer for Lyme Borreliosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07226882. Target conditions include Lyme Borreliosis.

What happened to similar drugs?

0 of 2 similar drugs in Lyme Borreliosis were approved

Approved (0) Terminated (0) Active (2)

🔄VLA15PfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07226882	Phase 3	Recruiting	Nov 19, 2025	Feb 14, 2028	Lyme Borreliosis
NCT04801420	Phase 2	Completed	Mar 8, 2021	Jul 2, 2025	Lyme Borreliosis
NCT03970733	Phase 2	Completed	Jul 1, 2019	Mar 28, 2022	Lyme Borreliosis
NCT03769194	Phase 2	Completed	Dec 17, 2018	Oct 2, 2020	Lyme Borreliosis

Competing Products

8 competing products in Lyme Borreliosis

See all competitors

Product	Company	Stage	Hype Score
mRNA-1975	Moderna	Phase 2	0
VLA15 with Alum + VLA15 without Alum	Pfizer	Phase 1	29
VLA15 + Placebo	Pfizer	Phase 2	35
VLA15 + Placebo	Pfizer	Phase 2	35
VLA15	Pfizer	Phase 3	44
VLA15	Pfizer	Phase 3	40
VLA15 + Placebo	Pfizer	Phase 2	35
Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine + Multivalent recombinant OspA Lyme Borreliosis Vaccine	Baxter	Phase 1/2	29